文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射化疗作为视网膜母细胞瘤辅助治疗的作用:系统综述与单臂Meta分析

The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2024-12-17

该系统综述与单臂Meta分析纳入25项研究共1082只眼,评估玻璃体腔注射化疗(IVitC)治疗视网膜母细胞瘤的临床结局。总体眼球摘除率为24.70%(95%CI 19.20-31.18%),马法兰组27.76%、拓扑替康组14.23%、联合组23.82%(P<.05);IAC+IVitC组眼球摘除率21.54%低于IVC+IVitC组的35.50%(P<.05)。作者认为IVitC是有效策略,尤其在接受IAC后给药时,但马法兰视网膜毒性仍是挑战。

要点

  • 25项研究1082只眼,总体眼球摘除率24.70%(95%CI 19.20-31.18%)。
  • 马法兰组眼球摘除率27.76%,拓扑替康组14.23%,联合组23.82%(P<.05)。
  • 马法兰组色素性视网膜病变率36.56%,拓扑替康组2.42%(P<.05)。

核心结论

  • IVitC是视网膜母细胞瘤的有效策略,尤其在接受IAC后给药时,但马法兰视网膜毒性仍是挑战。
  • 拓扑替康结果有前景但研究稀少,需比较两药以确定最佳治疗策略。

研究设计与样本

  • 系统综述与单臂Meta分析,检索MEDLINE、EMBASE和Cochrane,纳入所有报告IVitC用于视网膜母细胞瘤且报告安全性或有效性结局的文章,不限发表时间,排除少于10只眼的研究。
  • 共纳入25项研究、1082只眼;采用比例和95%CI计算眼球摘除率,使用R Studio中的随机效应模型进行分析。

主要发现

  • 马法兰单独用于687只眼(63.49%),拓扑替康单独用于104只眼(9.61%),联合用药用于291只眼(26.90%)。
  • 总体眼球摘除率为24.70%(95%CI 19.20-31.18%);亚组分析马法兰组27.76%(95%CI 19.05-38.55%)、拓扑替康组14.23%(95%CI 5.61-21.66%)、联合组23.82%(95%CI 11.95-41.87%),P<.05。
  • 实施IAC+IVitC的研究眼球摘除率为21.54%(95%CI 15.57-29.01%),使用IVC+IVitC的研究为35.50%(95%CI 20.73-53.66%),P<.05。
  • 马法兰组色素性视网膜病变率为36.56%(95%CI 24.61-50.44%),拓扑替康组为2.42%(95%CI 0.70-8.01%),P<.05。
  • 其他不良事件包括白内障(17.76%)、玻璃体出血(12.10%)和视网膜脱离(5.62%)。

关键数值与推荐

  • 纳入标准为报告IVitC用于视网膜母细胞瘤且报告安全性或有效性结局的所有文章,排除少于10只眼的研究。
  • 除1项研究外,所有研究均被判定存在严重偏倚风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究局限性在于缺乏关于该主题的大型随机研究。
  • 除1项研究外,所有研究均被判定存在严重偏倚风险。
  • 拓扑替康结果有前景但研究稀少。
  • 需比较两药以确定最佳治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: evaluation of clinical outcomes of patients with retinoblastoma treated with intravitreal chemotherapy (IvitC). DESIGN: Systematic review and single-arm meta-analysis CLINICAL RELEVANCE: Clinical outcomes with IVitC vary across reports according to patient characteristics and concomitant treatment modalities, mainly intravenous chemotherapy (IVC) and intra-arterial chemotherapy (IAC). There are currently no large clinical trials or meta-analyses focusing on the topic. METHODS: A systematic search was conducted in MEDLINE, EMBASE and Cochrane. All articles reporting use of IVitC for RB and safety or efficacy outcomes were included regardless of publication date. Studies with fewer than 10 eyes were excluded. Enucleation rates (ER) were calculated using proportions and 95% confidence intervals (CIs). The analysis was performed using the Random Effects model in R Studio. RESULTS: 25 studies comprising 1082 eyes met inclusion criteria. Melphalan was exclusively used in 687 eyes (63.49%), 104 eyes received topotecan exclusively (9.61%), and the remaining 291 (26.90%) used a combination. General ER was 24.70% (95% CI 19.20-31.18%). Subgroup analysis showed an ER of 27.76% (95% CI 19.05-38.55%) for melphalan, 14.23% (95% CI 5.61-21.66%) for topotecan, and 23.82% (95% CI 11.95-41.87%) for combination therapy (P < .05). It also revealed an ER of 21.54% (95% CI 15.57-29.01%) for studies that implemented IAC+IVitC versus 35.50% (95% CI 20.73-53.66%) for those who used IVC+IVitC (P < .05). Pigmentary retinopathy rate was 36.56% (95% CI 24.61-50.44%) in subjects treated with melphalan and 2.42% (95% CI 0.70-8.01%) for those receiving topotecan (P < .05). Other adverse events were cataract (17.76%) followed by vitreous hemorrhage (12.10%) and retinal detachment (5.62%). All studies, except 1, were determined to have a serious risk of bias. CONCLUSION: IVitC represents an effective strategy for retinoblastoma, especially when administered after IAC; however, melphalan retinal toxicity still poses a challenge. Results with topotecan are promising but scarce. Comparing both drugs is needed to define the best treatment strategy. This study is limited by the lack of large, randomized studies on this subject.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bravo-Gonzalez A, Dominguez-Ruiz P, González M, et al. The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis. Am J Ophthalmol. 2024. PMID: 39701510. doi:10.1016/j.ajo.2024.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。